Multi-Laboratory Evaluation of Prototype Dried Blood Spot Quality Control Materials for Creatine Kinase-MM Newborn Screening Assays

Abstract

by Paul Dantonio,Norma P. Tavakoli,Brooke Migliore,Elizabeth McCown,Timothy Lim,Sunju Park,Michele Caggana,Katerina S. Kucera,Han Phan,Natalie Street,Konstantinos Petritis andRobert F. Vogt
Int. J. Neonatal Screen. 2023, 9(1), 13; https://doi.org/10.3390/ijns9010013 - 5 July 2023
Cited by 3 | Viewed by 2359
Abstract
Pilot studies to detect newborns with Duchenne Muscular Dystrophy (DMD) by newborn bloodspot screening (NBS) have been conducted under the New York State Newborn Screening Program (NYS) and are currently in progress as part of the Early Check Program at Research Triangle Institute (RTI) International. The Newborn Screening Quality Assurance Program (NSQAP) at the U.S. Centers for Disease Control and Prevention (CDC) produced a set of seven prototype dried blood spot (DBS) reference materials spiked with varying levels of creatine kinase MM isoform (CK-MM). These DBS were evaluated over a 3-week period by CDC, NYS, and RTI, all using the same CK-MM isoform-specific fluoroimmunoassay. Results from each laboratory were highly correlated with the relative proportion of CK-MM added to each of the six spiked pools. Based on reference ranges established by NYS and RTI for their pilot studies, these contrived DBS collectively spanned the CK-MM ranges found in typical newborns and the elevated ranges associated with DMD. This set allows quality assessment over the wide range of fluctuating CK-MM levels in typical and DMD-affected newborns. Full article
► Show Figures
4 pages, 195 KiB
Open AccessOpinion